ABOUT HIGHTIDE

East Meets West - the Quest for Cure

Who We Are

Founded in Shenzhen, China, HighTide Therapeutics is a global clinical-stage biopharmaceutical company focused on discovering and developing novel drugs to treat chronic liver diseases, gastrointestinal diseases and metabolic disorders with high unmet needs. The company integrates expertise in disease biology, medicinal chemistry, clinical development and regulatory affairs to advance its growing pipeline of drugs. The company’s lead drug candidate, HTD1801, is a
first-in-class new molecular entity, currently in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). The FDA has granted HTD1801 Fast Track Designation in both diseases.

Our Mission

HighTide Therapeutics is dedicated to the discovery and development of innovative therapeutics for people suffering from chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unsatisfied market needs.

Leadership Team

Advisors

We will contact you as soon as possible

© 2020 HighTide Therapeutics Inc.

Legal StatementPrivacy PolicyCookie Policy

收起

Follow Us

© 2020 HighTide Therapeutics Inc.